Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin Pharmacol. 2020;88:4311–27.

Article  PubMed  Google Scholar 

Binns C, Lee M, Low WY. The long-term public health benefits of breastfeeding. Asia Pac J Public Health. 2016;28:7–14.

Article  PubMed  Google Scholar 

Victora CG, Bahl R, Barros AJD, França GVA, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. The Lancet. 2016;387:475–90.

Article  Google Scholar 

Hamdan A, Tamim H. The relationship between postpartum depression and breastfeeding. Int J Psychiatry Med. 2012;43:243–59.

Article  PubMed  Google Scholar 

Yeung CHT, Ito S, Autmizguine J, Edginton AN. Incorporating breastfeeding-related variability with physiologically based pharmacokinetic modelling to predict infant exposure to maternal medication through breast milk: a workflow applied to lamotrigine. AAPS J. 2021;23:1–11.

Google Scholar 

Suryavanshi SV, Wang S, Hajducek DM, Hamadeh A, Yeung CHT, Maglalang PD, et al. Coupling pre- and postnatal infant exposures with physiologically based pharmacokinetic modelling to predict cumulative maternal levetiracetam exposure during breastfeeding. Clin Pharmacokinet [Internet]. 2024;63:1735–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clin Pharmacokinet. 2018;57:1603–11.

Article  CAS  PubMed  Google Scholar 

Garessus EDG, Mielke H, Gundert-Remy U, Frontiers Media S.A. Exposure of infants to isoniazid via breast milk after maternal drug intake of recommended doses is clinically insignificant irrespective of metaboliser status. A physiologically-based pharmacokinetic (PBPK) modelling approach to estimate drug exposure of infants via breast-feeding. Front Pharmacol. 2019;10:1–13.

Article  Google Scholar 

Yeung CHT, Bertrand KA, Best BM, Capparelli E, Chambers CD, Hajducek DM, et al. Cannabidiol exposure through maternal marijuana use: predictions in breastfed infants. Clin Pharmacokinet. 2023;62:1611–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeung CHT, Autmizguine J, Dalvi P, Denoncourt A, Ito S, Katz P, et al. Maternal ezetimibe concentrations measured in breast milk and its use in breastfeeding infant exposure predictions. Clin Pharmacokinet. 2024;63:317–32.

Article  CAS  PubMed  Google Scholar 

Walczak-Nowicka ŁJ, Herbet M. Sodium benzoate—harmfulness and potential use in therapies for disorders related to the nervous system: a review. Nutrients. 2022;14:1–25.

Article  Google Scholar 

Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110:179–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Summar M. Current strategies for the management of neonatal urea cycle disorders. J Paediatr. 2001;138:S30–9.

Article  CAS  Google Scholar 

Parmeggiani B, Vargas CR. Oxidative stress in urea cycle disorders: findings from clinical and basic research. Clin Chim Acta. 2018;477:121–6.

Article  CAS  PubMed  Google Scholar 

Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100:S3-12.

Article  CAS  PubMed  Google Scholar 

Herder M. Orphan drug incentives in the pharmacogenomic context: Policy responses in the USA and Canada. J Law Biosci. 2016;3:158–66.

Article  PubMed  PubMed Central  Google Scholar 

Kakkilaya A, Shahzad M, Bourgeois FT. FDA approval of orphan drug indications for paediatric patients, 2011-2023. JAMA Pediatr. 2025;179:203.

Article  PubMed  PubMed Central  Google Scholar 

MacArthur RB, Altincatal A, Tuchman M. Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. Mol Genet Metab. 2004;81:67–73.

Article  Google Scholar 

Ucyclyd Pharma Inc. Ammonul Drug Label [Internet]. Scottsdale, AZ; 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020645lbl.pdf. Accessed 19 Mar 2024.

Häberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42:1192–230.

Article  PubMed  Google Scholar 

Endo F, Nakamura K, Sano Y, Dote N, Shimizu K, Koumura E. Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: a phase I, single-center, open-label study. Drug Metab Pharmacokinet. 2023;48:1–6.

Article  Google Scholar 

Lin YS, Mao WC, Yao NT, Tsai GE. Pharmacokinetics and safety of sodium benzoate, a d-amino acid oxidase (DAAO) Inhibitor, in healthy subjects: a phase I, Open-label Study. Clin Ther. 2022;44:1326–35.

Article  CAS  PubMed  Google Scholar 

Kubota K, Ishizaki T. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol. 1991;41:363–8.

Article  CAS  PubMed  Google Scholar 

Kubota K, Horai Y, Kushida K, Ishizaki T. Determination of benzoic acid and hippuric acid in human plasma and urine by high performance liquid chromatography. J Chromatogr. 1988;425:67–75.

Article  CAS  PubMed  Google Scholar 

Green TP, Marchessault RP, Freese DK, Minneapolis M. Disposition of sodium benzoate in newborn infants with hyperammonemia. J Pediatr. 1983;102:785–90.

Article  CAS  PubMed  Google Scholar 

Rog AA, van Ginneken CAM. Development of a consistent pharmacokinetic model for the disposition of benzoic acid and hippuric acid in man. Pharm Weekbl Sci. 1982;4:207–207.

Google Scholar 

Zu K, Pizzurro DM, Lewandowski TA, Goodman JE. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts. Regul Toxicol Pharmacol. 2017;89:83–94.

Article  CAS  PubMed  Google Scholar 

Rohwer JM, Schutte C, van der Sluis R. Functional characterisation of three glycine N-acyltransferase variants and the effect on glycine conjugation to benzoyl–CoA. Int J Mol Sci. 2021;22:1–19.

Article  Google Scholar 

Schwab AJ, Tao L, Yoshimura T, Simard A, Barker F, Pang AKS, et al. Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. Am J Physiol Gastrointest Liver Physiol. 2001;280:G1124–36.

Article  CAS  PubMed  Google Scholar 

Vessey DA, Kelley M, Warren RS. Characterization of the CoA ligases of human liver mitochondria catalyzing the activation of short-and medium-chain fatty acids and xenobiotic carboxylic acids. Biochim Biophys Acta. 1999;1428:455–62.

Article  CAS  PubMed  Google Scholar 

Vijay N, Morris ME. Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des. 2014;20:1497–8.

Article  Google Scholar 

Droździk M, Szeląg-pieniek S, Grzegółkowska J, Łapczuk-romańska J, Post M, Domagała P, et al. Monocarboxylate transporter 1 (MCT1) in liver pathology. Int J Mol Sci. 2020;21:1–12.

Article  Google Scholar 

Kido Y, Tamai I, Mototsugu O, Suzuki F, Tsuji A. Functional clarification of MCT1- mediated transport of monocarboxylic acids at the blood- brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm Res. 2000;17:1–8.

Article  Google Scholar 

Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10:193–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagic M, Milosevic V, Parojcic J, Cvijic S. Physiologically-based in silico modelling for the assessment of sodium benzoate bioperformance. In: Arhiv za Farmaciju Conference: 11th Central European Symposium on Pharmaceutical Technology. Belgrade, Serbia: Pharmaceutical Association of Serbia; 2016. p. 117–8.

Breitkreutz J, Bornhöft M, Wöll F, Kleinebudde P. Paediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder. Eur J Pharm Biopharm. 2003;56:247–53.

Article  CAS  PubMed